Read about progress with SRA737 on page 5 Operational highlights â€¢ Lead cancer drug candidate SRA737 (formerly CCT245737), a novel Chk1 inhibitor, licensed for clinical development and commercialisation to NASDAQ-listed company Sierra Oncology, Inc.